These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 15962607)

  • 1. [Cardiovascular risk factors in dialyzed patients].
    Kobus G; Małyszko J; Myśyliwiec M
    Pol Arch Med Wewn; 2004 Dec; 112(6):1425-31. PubMed ID: 15962607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular complications in patients with diabetic nephropathy receiving pharmacological versus renal replacement therapy.
    Głowińska I; Grochowski J; Małyszko J
    Pol Arch Med Wewn; 2008; 118(7-8):404-12. PubMed ID: 18714735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors modulating cytosolic calcium. Role in lipid metabolism and cardiovascular morbidity and mortality in peritoneal dialysis patients.
    Gadallah MF; el-Shahawy M; Andrews G; Ibrahim M; Ramdeen G; Hanna D; Gorospe W; Morkos A; Abbassian M; Moles K
    Adv Perit Dial; 2001; 17():29-36. PubMed ID: 11510292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Left ventricular hypertrophy in patients on hemodialysis: importance of anemia].
    Stojimirović B; Petrović D; Obrenović R
    Med Pregl; 2007; 60 Suppl 2():155-9. PubMed ID: 18928184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Selected parameters of bone metabolism in hemodialyzed and peritoneally dialyzed patients].
    Małyszko J; Zbroch E; Wołczyński S; Myśliwiec M
    Przegl Lek; 2000; 57(12):711-3. PubMed ID: 11398592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Characteristics of hyperhomocysteinemia in dialysis patients].
    Lovcić V; Kes P; Reiner Z
    Acta Med Croatica; 2006; 60(1):21-6. PubMed ID: 16802568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural changes in carotid arteries and impairment of fibrinolysis in hemodialyzed and peritoneally dialyzed patients.
    Małyszko J; Łebkowska U; Małyszko JS; Myśliwiec M
    Med Sci Monit; 2009 Dec; 15(12):CR644-9. PubMed ID: 19946236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients.
    Helal I; Smaoui W; Hamida FB; Ouniss M; Aderrahim E; Hedri H; Elyounsi F; Maiz HB; Abdallah TB; Kheder A
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):59-62. PubMed ID: 20061694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender differences in mediators of left ventricular hypertrophy in dialysis patients.
    Savage T; Giles M; Tomson CV; Raine AE
    Clin Nephrol; 1998 Feb; 49(2):107-12. PubMed ID: 9524781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Concentration of leptin in patients on hemodialysis and peritoneal dialysis].
    Zbroch E; Małyszko J; Wołczyński S; Hryszko T; Myśliwiec M
    Pol Arch Med Wewn; 1999 Jun; 101(6):503-8. PubMed ID: 10754736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular disease in peritoneal dialysis.
    Prichard S; Sniderman A; Cianflone K; Marpole D
    Perit Dial Int; 1996; 16 Suppl 1():S19-22. PubMed ID: 8728157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients.
    Wang AY; Wang M; Woo J; Lam CW; Lui SF; Li PK; Sanderson JE
    J Am Soc Nephrol; 2004 Aug; 15(8):2186-94. PubMed ID: 15284304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type of renal replacement therapy and residual renal function may affect prohepcidin and hepcidin.
    Malyszko J; Malyszko JS; Kozminski P; Mysliwiec M
    Ren Fail; 2009; 31(10):876-83. PubMed ID: 20030521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinogen and calcium x phosphate product are predictors of cardiovascular events in the CAPD population.
    Enia G; Panuccio V; Mallamaci F; Tripepi G; Mandalari A; Zoccali C
    J Nephrol; 2005; 18(6):764-9. PubMed ID: 16358236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H; Baradaran A
    J Ayub Med Coll Abbottabad; 2004; 16(2):3-8. PubMed ID: 15455608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between serum magnesium and risk factors of cardiovascular disease in hemodialysis patients.
    Khatami MR; Mirchi E; Khazaeipour Z; Abdollahi A; Jahanmardi A
    Iran J Kidney Dis; 2013 Jan; 7(1):47-52. PubMed ID: 23314142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemoglobin levels, cardiovascular disease, and left ventricular hypertrophy in patients with chronic kidney disease. Case study of the anemic patient.
    Butler KG
    Nephrol Nurs J; 2002 Apr; 29(2):189-92. PubMed ID: 11997954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular problems in the choice of dialysis therapy for the elderly.
    Maiorca R
    Contrib Nephrol; 1994; 106():74-83. PubMed ID: 8174382
    [No Abstract]   [Full Text] [Related]  

  • 19. Left ventricular hypertrophy and blood pressure control in automated and continuous ambulatory peritoneal dialysis patients.
    Ataş N; Erten Y; Okyay GU; Inal S; Topal S; Öneç K; Akyel A; Çelik B; Tavil Y; Bali M; Arınsoy T
    Ther Apher Dial; 2014 Jun; 18(3):297-304. PubMed ID: 24965296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients.
    Frank H; Heusser K; Höffken B; Huber P; Schmieder RE; Schobel HP
    Kidney Int; 2004 Aug; 66(2):832-40. PubMed ID: 15253740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.